Literature DB >> 21088983

A case of resistance to clopidogrel and prasugrel after percutaneous coronary angioplasty.

M Silvano1, C F Zambon, G De Rosa, M Plebani, V Pengo, M Napodano, R Padrini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21088983     DOI： 10.1007/s11239-010-0533-x

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


× No keyword cloud information.
  13 in total

1.  Use of omeprazole sulfone in a single plasma sample as a probe for CYP3A4.

Authors:  Ylva Böttiger
Journal:  Eur J Clin Pharmacol       Date:  2006-06-22       Impact factor: 2.953

2.  The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin.

Authors:  Thomas A Clarke; Lucy A Waskell
Journal:  Drug Metab Dispos       Date:  2003-01       Impact factor: 3.922

3.  Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation.

Authors:  Ankie Harmsze; Jochem W van Werkum; Heleen J Bouman; Henk J Ruven; Nicolien J Breet; Jurrien M Ten Berg; Christian M Hackeng; Mathieu M Tjoeng; Olaf H Klungel; Anthonius de Boer; Vera H Deneer
Journal:  Pharmacogenet Genomics       Date:  2010-01       Impact factor: 2.089

4.  Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects.

Authors:  Pierre Fontana; Annabelle Dupont; Sophie Gandrille; Christilla Bachelot-Loza; Jean-Luc Reny; Martine Aiach; Pascale Gaussem
Journal:  Circulation       Date:  2003-08-11       Impact factor: 29.690

5.  Simultaneous subacute coronary drug-eluting stent thrombosis in two different vessels of a patient with factor V Leiden mutation.

Authors:  Parham Eshtehardi; Masoud Eslami; Davood Akhlagh Moayed
Journal:  J Cardiovasc Med (Hagerstown)       Date:  2008-04       Impact factor: 2.160

Review 6.  Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations.

Authors:  Kyle J Ellis; George A Stouffer; Howard L McLeod; Craig R Lee
Journal:  Pharmacogenomics       Date:  2009-11       Impact factor: 2.533

7.  Cytochrome p-450 polymorphisms and response to clopidogrel.

Authors:  Jessica L Mega; Sandra L Close; Stephen D Wiviott; Lei Shen; Richard D Hockett; John T Brandt; Joseph R Walker; Elliott M Antman; William Macias; Eugene Braunwald; Marc S Sabatine
Journal:  N Engl J Med       Date:  2008-12-22       Impact factor: 91.245

8.  Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance.

Authors:  Wei C Lau; Paul A Gurbel; Paul B Watkins; Charlene J Neer; Amy S Hopp; David G M Carville; Kirk E Guyer; Alan R Tait; Eric R Bates
Journal:  Circulation       Date:  2004-01-05       Impact factor: 29.690

9.  Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome.

Authors:  P Michael Ho; Thomas M Maddox; Li Wang; Stephan D Fihn; Robert L Jesse; Eric D Peterson; John S Rumsfeld
Journal:  JAMA       Date:  2009-03-04       Impact factor: 56.272

10.  The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study.

Authors:  J D Balian; N Sukhova; J W Harris; J Hewett; L Pickle; J A Goldstein; R L Woosley; D A Flockhart
Journal:  Clin Pharmacol Ther       Date:  1995-06       Impact factor: 6.875
View more
  2 in total

1.  Oral antiplatelet therapy and platelet inhibition: An experience from a tertiary care center.

Authors:  Jamshed J Dalal; Aarti Digrajkar; Alap Gandhi
Journal:  Indian Heart J       Date:  2016-01-14

Review 2.  Type 2 Diabetes and ADP Receptor Blocker Therapy.

Authors:  Matej Samoš; Marián Fedor; František Kovář; Michal Mokáň; Tomáš Bolek; Peter Galajda; Peter Kubisz; Marián Mokáň
Journal:  J Diabetes Res       Date:  2015-12-28       Impact factor: 4.011
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.